GSTM1 polymorphism in Oncotype DX assay is a potential predictive factor for taxane-based neoadjuvant chemotherapy in estrogen receptor-positive Chinese breast cancer patients

BACKGROUND: Investigations of the 21-gene Oncotype DX assay in neoadjuvant settings for breast cancer patients are currently underdeveloped. It is still unclear whether any individual gene of the 16 cancer-related genes can be used to predict response to taxane-based neoadjuvant chemotherapy. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Guochun, Qian, Xueke, Ren, Chongyang, Wen, Lingzhu, Lyu, Haitong, Liao, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797896/
https://www.ncbi.nlm.nih.gov/pubmed/35116798
http://dx.doi.org/10.21037/tcr.2019.04.03

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797896/
https://www.ncbi.nlm.nih.gov/pubmed/35116798
http://dx.doi.org/10.21037/tcr.2019.04.03

Ejemplares similares